UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Filed by a Party other than the Registrant o
Check the appropriate box:
| o | Preliminary Proxy Statement | |
| o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| o | Definitive Proxy Statement | |
| o | Definitive Additional Materials | |
| þ | Soliciting Material Pursuant to §240.14a-12 |
Lexicon Pharmaceuticals, Inc.
Payment of Filing Fee (Check the appropriate box):
| þ | No fee required. | |
| o | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: | ||
| (2) | Aggregate number of securities to which transaction applies: | ||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | ||
| (4) | Proposed maximum aggregate value of transaction: | ||
| (5) | Total fee paid: | ||
| o | Fee paid previously with preliminary materials. | |
| o | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: | ||
| (2) | Form, Schedule or Registration Statement No.: | ||
| (3) | Filing Party: | ||
| (4) | Date Filed: | ||
News Release
FOR IMMEDIATE RELEASE
LEXICON PHARMACEUTICALS ANNOUNCES TWO AGREEMENTS TO FINANCE
LONG-TERM DRUG DEVELOPMENT STRATEGY
LONG-TERM DRUG DEVELOPMENT STRATEGY
INVUS TO INVEST $205 MILLION IN COMMON STOCK AT SIGNIFICANT PREMIUM
SYMPHONY TO FUND ADDITIONAL $60 MILLION TO ADVANCE FIRST THREE DRUGS
The Woodlands, Texas, June 17, 2007 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has entered
into a major financing agreement with The Invus Group, LLC (“Invus”) to help fund its strategic
goal of transitioning into an integrated biopharmaceutical company. Under the agreement, Invus
will invest $205M in 2007 with the potential for up to an additional $345M over the next four
years.
Simultaneously, Lexicon announced it has entered into a $60 million product development
collaboration with Symphony Capital Partners, L.P. and its co-investors (“Symphony”) to move its
first three drug candidates into advanced clinical development:
| • | LX6171 for cognitive disorders — currently completing Phase 1b | |
| • | LX1031 for irritable bowel syndrome — currently in Phase 1b, and | |
| • | LX1032 for gastrointestinal disorders — currently in preclinical development |
“We have developed a long-term financial framework upon which we are building an integrated
biopharmaceutical company. With Invus and Symphony, Lexicon will have substantially greater
resources and flexibility to aid in fulfilling our mission to discover and develop breakthrough
treatments for human disease,” said Arthur T. Sands, M.D., Ph.D., founder, president and chief
executive officer of Lexicon. “We have accomplished groundbreaking target discovery work,
resulting in a portfolio of more than 100 promising new targets, and have built an exciting
pipeline of both antibody and small molecule drug candidates.”
“We have chosen to partner with Lexicon’s talented scientists and management team because we
believe that, with our commitment as a long-term shareholder with significant capital, Lexicon has
the potential to become a major biopharmaceutical company,” said Raymond Debbane, founder and
president of The Invus Group, LLC.
Summary of the Invus Transaction
Under the agreement, which the Lexicon board of directors has approved, Invus has received warrants
to purchase 16.5 million shares of Lexicon common stock, for a per share purchase price of $3.09,
the ten-day volume weighted average as of June 14, 2007. Upon shareholder approval, Invus will
purchase, at that price, the number of shares that remain subject to the warrants, and the warrants
will terminate. Invus also will purchase approximately 34.3 million
Page 2 of 6
additional shares of common stock which, when added to the shares already owned by Invus, will
bring Invus’ ownership to 40% of the post-transaction outstanding shares of common stock. The
purchase price for these additional 34.3 million shares will be $4.50, a 46% premium over the
Friday, June 15th, 2007 closing price of $3.08.
To assure long-term adequate financing, Invus will have the right to require the company to
initiate up to two rights offerings, which would provide all shareholders with pro rata rights to
acquire additional common stock in an aggregate amount not to exceed $345 million. The first
rights offerings may be initiated, subject to certain adjustments, beginning 27 months from the
closing of the initial investment, and the second rights offering may be initiated beginning 12
months after the initiation of the first, or 39 months from the closing of the initial investment
if the first rights offering does not take place. The initial investment and subsequent rights
offerings are designed to achieve up to approximately $550 million in proceeds to Lexicon. Invus
would participate in the rights offering for up to its pro rata portion of the offering, and would
commit to purchase the entire portion of the offering not subscribed for by other stockholders.
As part of its agreement with Invus, Lexicon will have the right to issue common stock before the
commencement of the rights offerings at a price above $4.50 per share. Such offerings will reduce
the total amount required to be raised under the rights offerings. Invus will have the right to
participate in future equity issuances by the company so as to maintain its percentage ownership of
the company. Invus will also agree to customary standstill restrictions that will not apply to the
rights offerings and will have other exceptions. Invus will have initially three members on the
Lexicon board of directors, which will be expanded from eight to eleven members.
The transaction will be submitted to Lexicon stockholders for approval at a meeting planned for
August or September.
“We are implementing a long-term financial strategy that will fuel our extensive drug discovery and
development pipeline,” said Julia P. Gregory, executive vice president and chief financial officer.
“Taken together, the Invus and Symphony agreements substantially reduce financing risk and enhance
our drug development expertise, while allowing all shareholders to continue to participate in
Lexicon’s growth. This strong financial backing will complement Lexicon’s corporate partnering
strategy to accelerate the development and commercialization of our products.”
Summary of the Symphony Transaction
Under the terms of the $60 million Symphony transaction, $45 million has been provided to Symphony
Icon, Inc., a newly-created company that was established to accelerate development of Lexicon’s
first three product candidates and hold the license to the intellectual property of LX6171, LX1031
and LX1032. An additional $15 million of equity capital was provided directly to Lexicon for
general corporate purposes.
Page 3 of 6
Through a purchase option, Lexicon retains the exclusive right, but not the obligation, to acquire
100% of the equity of Symphony Icon at exercise prices that range from $72 million in the second
year up to $90 million in the fourth year of the collaborative development period. The option
exercise may be paid in cash or a combination of cash and Lexicon common stock at Lexicon’s sole
discretion. If Lexicon chooses not to exercise the purchase option, Symphony Icon will retain the
rights to the three programs. In exchange for the purchase option and $60 million of funding,
Lexicon issued approximately 7.7 million shares of Lexicon common stock to Symphony Icon’s
investors at a purchase price of $3.14, the ten-day closing price average as of June 12, 2007. The
collaboration is intended to last up to four years.
“Our collaboration with Symphony provides capital as well as additional drug development expertise
to further the clinical development of LX1031, LX1032 and LX6171,” said Arthur T. Sands, M.D.,
Ph.D., Lexicon’s founder, president and chief executive officer. “The structure of the
collaboration also provides Lexicon with the unique opportunity to develop these lead product
candidates rapidly while we retain exclusive rights. Simultaneously, we expand our early-stage
pipeline of drug candidates in the Lexicon 10TO10 Program to achieve 10 drug candidates
in clinical development through 2010. Our agreement with Symphony affords Lexicon the flexibility
to partner with pharmaceutical companies at a more advanced stage of development.”
In accordance with Financial Accounting Standards Board Interpretation No. 46 regarding variable
interest entities, Lexicon will consolidate the results of operations of Symphony Icon into its
financial statements beginning with the filing of its second quarter 2007 financial statements.
Symphony Icon will be governed by a board of directors comprised of Arthur T. Sands, M.D., Ph.D.,
Lexicon’s founder, president and chief executive officer; two representatives of Symphony Capital,
Mark Kessel and Jeffrey S. Edelman; and two independent Board members, Steven H. Ferris, Ph.D.,
executive director of the NYU Silberstein Aging and Dementia Research Center, and Douglas A.
Drossman, M.D., professor of medicine and psychiatry, UNC School of Medicine, Division of
Gastroenterology & Hepatology and Co-Director of the UNC Center for Functional GI & Motility
Disorders.
Symphony Icon has retained RRD International, LLC, a regulatory and clinical development advisory
group, to serve as Symphony Icon’s management team. Lexicon will continue to lead the development
of LX1031, LX1032 and LX6171.
Advisors
Morgan Stanley & Co. Incorporated and Vinson & Elkins LLP represent Lexicon in the Invus
transaction. Cahill Gordon & Reindel LLP advised Lexicon’s board of directors.
Simpson Thacher & Bartlett LLP represents Invus in the Invus transaction.
Paul, Weiss, Rifkind, Wharton & Garrison LLP represents Symphony in the Symphony Icon transaction.
Page 4 of 6
Conference Call Tomorrow, Monday, June 18th
Lexicon management will hold a conference call tomorrow to discuss the Invus investment and the
Symphony Icon collaboration at 8:30 a.m. Eastern Time. The dial-in number for the conference call
is 800-289-0485 (within the United States) or 913-981-5518 (international). The passcode for all
callers is 4692046. Investors can access www.lexpharma.com to listen to a live webcast of the
call.
About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough
treatments for human disease. Lexicon currently has clinical programs underway for such areas of
major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used
its proprietary gene knockout technology to discover more than 100 promising drug targets and
create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of
diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer,
immune system disorders and ophthalmic disease. To advance the development and commercialization
of its programs, Lexicon is working both independently and through collaborators including
Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company
Limited. For additional information about Lexicon and its programs, please visit
www.lexpharma.com.
About Invus Group
Invus is a New York-based investment firm with additional offices in London and Paris. Invus
invests in a variety of equity transactions, including buyouts, longer term public equity
investments, venture capital, and expansion financings. Invus manages in excess of $4 billion of
capital. Invus has achieved both cash on cash multiples and annual internal rates of return over
22 years that are at the very top of the private equity industry. Invus manages interests in a
broad range of industries, including consumer goods, consumer services, education, software,
biotechnology and medical devices.
The Invus principals draw on their broad experience in partnering with management teams and boards
to help formulate and execute strategies that maximize long-term value.
About Symphony Capital Partners, L.P.
Symphony Capital is a New York-based private equity firm that invests in development stage
biopharmaceutical programs. Symphony has the most experienced team in R&D project-specific
financings and invests exclusively in the type of collaboration undertaken with Lexicon. Symphony
Capital Partners, L.P. is the lead investor in Symphony Icon. Additional information about
Symphony is available at www.symphonycapital.com.
Page 5 of 6
About RRD International, LLC
RRD International, LLC (RRD) is an innovative product development company dedicated to supporting
the global regulatory, preclinical and clinical needs of biotechnology, pharmaceutical and medical
device companies. RRD provides comprehensive strategic planning and operational support from
program inception to product approval including the design, management and execution of clinical
trials. RRD’s team of highly experienced drug and device developers has a substantial record of
favorable FDA interactions and outcomes. Through its customized and flexible business approach,
RRD offers a unique risk-sharing model, enabling its goals and interests to be aligned with a
partner company’s success. Additional information about RRD is available at www.rrdintl.com.
Lexicon Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to, without
limitation, all statements regarding the agreement with Invus to invest in Lexicon and the
agreement with Symphony Capital to provide capital to advance Lexicon’s development of LX1031,
LX1032 and LX6171, Lexicon’s growth and future operating results, discovery and development of
products, strategic alliances and intellectual property, as well as other matters that are not
historical facts or information. All forward-looking statements are based on management’s current
assumptions and expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon’s ability to successfully conduct preclinical and
clinical development of its potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing, intellectual property rights,
and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual
results to be materially different from any future results expressed or implied by such
forward-looking statements. Information identifying such important factors is contained under
“Factors Affecting Forward-Looking Statements” and “Risk Factors” in Lexicon’s annual report on
Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or revise any such forward-looking
statements, whether as a result of new information, future events or otherwise.
Lexicon will file a proxy statement and other documents with the Securities and Exchange Commission
relating to the approval of the Invus transactions. Stockholders are urged to carefully read the
proxy statement when it becomes available, because it will contain important information regarding
Lexicon and the Invus transactions. A definitive proxy statement will be sent to stockholders
seeking their approval of the Invus transactions. Stockholders may obtain a free copy of the proxy
statement (when it is available) and other documents containing information about Lexicon, without
charge, at the SEC’s web site at www.sec.gov. Copies of the definitive proxy statement and the SEC
filings that will be incorporated by reference in the proxy statement may also be obtained for free
by directing a request to Lexicon Pharmaceuticals, Inc. 8800 Technology Forest Place, The
Woodlands, Texas 77381, Attention: Corporate Communications.
Page 6 of 6
Lexicon and its officers and directors may be deemed to be participants in the solicitation of
proxies from the stockholders. Information about these persons can be found in Lexicon’s Annual
Report on Form 10-K filed with the SEC, and additional information about such persons may be
obtained from the proxy statement when it becomes available.
# # #
Contacts for Lexicon:
Investor Relations:
Bobbie Faulkner
281-863-3503
Bobbie Faulkner
281-863-3503
Media:
Steve Milunovich or Melissa Daly, Brunswick Group
212-333-3810
Steve Milunovich or Melissa Daly, Brunswick Group
212-333-3810
Contact for Symphony Capital LLC:
Jeffrey S. Edelman
212-632-5404
212-632-5404